Veracyte (VCYT) CCO Leite sells 5,260 shares under Rule 10b5-1 plan

Rhea-AI Filing Summary

VERACYTE, INC. Chief Commercial Officer-CLIA John Leite reported an open-market sale of common stock under a pre-arranged Rule 10b5-1 trading plan. On March 4, 2026, he sold 5,260 shares at a weighted average price of $35.1868 per share, with individual sale prices ranging from $35.00 to $35.53. After this transaction, he continued to hold 107,580 shares of Veracyte common stock directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leite John

(Last) (First) (Middle)

6000 SHORELINE COURT, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer-CLIA

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		S(1)		5,260	D	$35.1868(2)	107,580	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 9, 2025.

2. Represents weighted average sales price. Sale prices for the transactions range from $35.00 to $35.53. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

Remarks:

	/s/ Jonathan Wygant as attorney-in-fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Veracyte (VCYT) report for John Leite?

Veracyte reported that Chief Commercial Officer-CLIA John Leite sold 5,260 shares of common stock in an open-market transaction. The sale was executed under a Rule 10b5-1 trading plan, meaning the trades were pre-arranged according to preset instructions.

At what price did John Leite sell Veracyte (VCYT) shares?

John Leite sold 5,260 Veracyte common shares at a weighted average price of $35.1868 per share. The detailed footnote states that individual sale prices ranged from $35.00 to $35.53, with full price breakdowns available on request.

How many Veracyte (VCYT) shares does John Leite hold after this Form 4 sale?

Following the reported transaction, John Leite directly holds 107,580 shares of Veracyte common stock. This figure reflects his ownership after the sale of 5,260 shares disclosed in the Form 4 insider trading report filed for the March 4, 2026 transaction date.

Was the Veracyte (VCYT) insider sale by John Leite under a Rule 10b5-1 plan?

Yes. The filing notes that the transaction was made under a Rule 10b5-1 trading plan adopted by John Leite. Such plans allow insiders to schedule trades in advance, helping separate planned sales from day-to-day market decisions.

What does the Veracyte (VCYT) Form 4 say about the nature of John Leite’s ownership?

The Form 4 identifies John Leite’s ownership of these Veracyte shares as direct. The reported 107,580 shares following the transaction are held directly in his name, with no indication in the filing of indirect ownership through another entity.

What transaction code was used in the Veracyte (VCYT) Form 4 for John Leite?

The transaction is coded as “S”, indicating a sale in an open market or private transaction. The filing further describes it as an open-market sale of Veracyte common stock, consistent with the Rule 10b5-1 trading plan referenced in the footnotes.